Introduction {#s1}
============

Botanicals and their derivatives/preparations are used throughout Europe for health purposes, with increased usage in the general population as well as among specific subgroups encompassing children and pregnant women or those suffering from diseases such as cancer among others [@pone.0092265-MennitiIppolito1]--[@pone.0092265-Bishop1]. Botanicals are used in many different types of products, including foods, (teas and juices), food supplements such as plant food supplements (PFS), herbal medicinal products (HMP), homeopathic products, cosmetics, biocides etc [@pone.0092265-LarraagaGuetaria1]. These different product categories are regulated by specific legislation, depending on the intended use of the product.

The European Union (EU) Directive on Food Supplements (2002/46/EC) defines dietary supplements (which include PFS) as [@pone.0092265-European1]:

"...foodstuffs the purpose of which is to supplement the normal diet and which are concentrated sources of nutrients or other substances with a nutritional or physiological effect, alone or in combination, marketed in dose form, namely forms such as capsules, pastilles, tablets, pills and other similar forms, sachets of powder, ampoules of liquids, drop dispensing bottles and other similar forms of liquids and powders designed to be taken in measured small quantities".

The marketing of a product as a PFS however, depends on national legislation, which differs widely across Member States. Countries vary in the extent to which products are regulated, as well as in the process of regulatory control. Some countries have regulated the use of botanicals in detail (including negative and positive lists), some apply specific conditions of use, (including maximum usage levels or warnings for the consumer), and in others less specific requirements exist. An added complexity lies in the application of the basic European "principle of mutual recognition", whereby any product that is lawfully marketed in one Member State can be sold in all 27 Member States [@pone.0092265-LarraagaGuetaria1].

Moreover, the same botanical may be used as a food supplement and as a medicinal product, depending on the intended use of the product and both food supplements and medicinal products often share the same form of presentation (powders, pills or tablets). Hence the legal status of products differs from one country to another, resulting in a complex market environment. This so-called borderline issue between PFS and HMP is a major obstacle to the marketing of PFS in the European Union [@pone.0092265-LarraagaGuetaria1].

Plant food supplement usage data at EU level are scarce with reports providing PFS market data as opposed to data reported directly by the consumer [@pone.0092265-European2]. Surveys on the intake of botanicals have been conducted primarily in the context of the intake of dietary supplements in general [@pone.0092265-Skeie1] or as part of surveys of complementary and alternative medicine (CAM) therapies [@pone.0092265-VargasMurga1], and issues such as the legal distinction between HMP and PFS have not been taken into account. A recent systematic review evaluating the demographic characteristics and health status factors associated with CAM use reported that the majority of population based consumption studies had been conducted in the USA (64% of the 110 identified studies), and of these, 13% were in Europe, with the majority carried out in Scandinavia (7%) and the United Kingdom (5%) [@pone.0092265-Bishop1]. Studies have been limited by the heterogeneity of definitions used, study designs and objectives making it difficult to compare results and to extrapolate conclusions. The ambiguity of categories such as "natural medicine", "herbal remedies" or "herbal medicine" and what constitutes "dietary supplements" makes it nearly impossible to attain reliable estimates of the prevalence of PFS usage in Europe, with only limited data available at national levels [@pone.0092265-VargasMurga1]--[@pone.0092265-CentrodeInvestigacinsobre1] but not at the European level.

A study by the European Advisory Services (EAS) on "The use of substances with nutritional or physiological effect other than vitamins and minerals in food supplements" [@pone.0092265-European2], provided information on European market and regulation data, and highlighted the need for obtaining PFS usage data in order to plan, monitor and evaluate national and European policies, as in other regions of the world. One such example is the United States of America, where the Alternative Health/CAM supplement of the National Health Interview Survey (NHIS) has been collecting data on botanical dietary supplements for some years now [@pone.0092265-National1]--[@pone.0092265-Dwyer1].

The European Food Safety Authority (EFSA) has recognised the lack of data in the sector and has published a number of reports addressing related issues, namely the recommendations for reporting the use of supplements and medicines by adults in any pan-European dietary survey or project [@pone.0092265-EuropeanFoodSafety1], and the "Compendium of botanicals reported to contain naturally occurring substances of possible concern for human health", aimed to help with the safety assessment of botanicals and botanical preparations intended for use as food supplements [@pone.0092265-EuropeanFoodSafety2].

The purpose of this paper is to describe the type and frequency of PFS usage reported in a retrospective survey of consumers in six European countries; in addition we present the most frequently used botanical ingredients in these products. We also highlight the issues associated with measuring usage of PFS in European populations and make recommendations for future research.

Materials and Methods {#s2}
=====================

Ethics statement {#s2a}
----------------

Before initiating the fieldwork, approval for the conduct of the survey was obtained from four ethics committees: the Bioethics Commission of the University of Barcelona, Spain; the Ethics Committee of the University of Milano, Italy; the Ethical Committee of the Faculty of Medicine - Transilvania University of Brasov, Romania; and the Coordinating Ethics Committee, Hospital District of Helsinki and Uusimaa, Finland. Approval of the survey by these four ethics committees required submitting all survey material to their members for evaluation. No ethical approval for the survey was needed in Germany and the United Kingdom.

To ensure harmonisation and standardisation of the fieldwork and data collection across countries, a market research organization, *European Fieldwork Group* (EFG) was subcontracted to implement the survey. The survey was conducted by EFG in strict accordance with the ICC/ESOMAR Code on Market and Social Research. In all countries, informed consent was obtained verbally from all respondents after reading the survey information sheet. All data were recorded manually i.e. pen-and-paper. Recruitment of survey participants occurred in the selected cities in each country. Approximately the first 1000 individuals per country were systematically selected for screening i.e. intercepting 1 in every 5 individuals passing by to ask him/her the initial screening questions; subsequent screening selection was performed on a convenience basis i.e. intercepting individuals in places where consumers were likely to be found, such as herbal shops, pharmacies etc. Eligible respondents who agreed to participate were given an appointment at their home/workplace to complete the main survey. The appointments of those willing to participate were later reconfirmed by phone.

The data were made anonymous when recorded electronically i.e. the respondents\' contact details were not entered into the survey database. Instead, the market research organization assigned ID numbers to each respondent and provided PlantLIBRA partners only the database with the assigned ID numbers.

Definition of plant food supplements in the PlantLIBRA PFS consumer survey {#s2b}
--------------------------------------------------------------------------

Although there is a legal definition of Food Supplements (EU Directive (2002/46/EC) [@pone.0092265-European1] under which PFS reside, for the purposes of this research it was necessary to develop a specific definition of PFS whose main characteristic is that they contain botanical preparations as ingredients for food supplementation.

Botanical preparations are obtained by subjecting botanicals (plants, algae, fungi or lichens) to treatments such as comminution, extraction, distillation, squeezing, fractionation, purification, concentration or fermentation. These include extracts, essential oils, expressed juices, powders, etc.

Botanical preparations can be considered as *nutrients* or *other substances*. Thus, the definition of PFS for the survey was as follows: PFS are \"foodstuffs the purpose of which is to supplement the normal diet and which are concentrated sources of botanical preparations that have nutritional or physiological effect, alone or in combination with vitamins, minerals and other substances which are not plant-based. PFS are marketed in dose form, such as capsules, pastilles, tablets, pills and other similar forms, sachets of powder, ampoules of liquids, drop dispensing bottles, and other similar forms of liquids and powders designed to be taken in measured small unit quantities".

Products that did not meet this definition, such as herbal remedies and other medicinal products based on botanicals, and those that did not meet the PFS definition in terms of dosage, such as herbal teas or juices, were excluded.

Sample population and PFS consumer definition {#s2c}
---------------------------------------------

A cross-sectional, 12-month retrospective survey was conducted in 24 cities in six European countries -Finland, Germany, Italy, Romania, Spain and the United Kingdom. An estimated sample size of 2000 screened individuals per country was calculated in order to obtain a final sample of approximately 400 consumers per country (total N = 2400 approximately). Per country, gender and age group quotas were set as follows: 300 adults (18 to 59 years) and 100 older adults (60-and-over years), with 30--50% male and 50--70% female. All individuals were screened by means of a brief questionnaire which recorded PFS usage in the preceding 12 months. Individuals were considered eligible for inclusion if they were over 18 years old and met either of the following specified criteria, intended to capture the different usage patterns of PFS consumers:

1.  They had taken at least 1 PFS in the last 12 months, in an appropriate dose form at a minimum frequency of either:

    a.  1 daily dose for at least 2 consecutive or non-consecutive weeks, or

    b.  1 or more doses per week for at least 3 consecutive weeks or

    c.  1 or more doses per week for at least 4 consecutive or non-consecutive weeks

2.  They had taken 2 or more different PFS, in an appropriate dose form, at a minimum frequency of 1 or more doses per week, with the sum of the usage period of the 2 or more products being equal to at least 4 weeks.

Instruments and variables {#s2d}
-------------------------

A short screening questionnaire was used to identify consumers who met the survey inclusion criteria; it consisted of six questions which allowed interviewers to identify eligible consumers, based on the product(s) used, the frequency and duration of use and the dose form. Eligible consumers subsequently completed a more detailed questionnaire on their PFS usage in the preceding 12 months, providing details of product/plant names, dosage forms, frequency of use, reasons for use, adverse effects, places and patterns of purchase and information sources on products. These questions were asked for each of up to a maximum of 5 different PFS used. In addition, respondents were asked to provide socio-demographic data including age, gender, level of education and employment status, as well as self-reported height and weight and further health-related lifestyle information.

Survey administration and data collection {#s2e}
-----------------------------------------

Fieldwork and data collection for the cross-sectional survey were conducted by the international market research company EFG, from May 2011 to September 2012. The duration of the fieldwork ensured that any seasonal variability in usage of products was captured. The survey protocols and instruments -training material, information sheet, informed consent, screening and usage questionnaires-, were initially developed in English by consensus amongst the research team, and subsequently translated into the respective languages in each of the survey countries. Pilot interviews were conducted in each participating country to assess the comprehension of the questions and to determine the time required to complete the survey.

In each participating country, trained interviewers systematically screened approximately 1000 individuals during the first three months of the survey, which allowed the estimation of the prevalence rate. Subsequently, screening and recruitment were conducted on a convenience basis. The recruited eligible consumers were interviewed face-to-face and the more detailed PFS usage questionnaire completed.

Data preparation and statistical analysis {#s2f}
-----------------------------------------

All data from the completed surveys were entered into the statistical package SPSS for Windows v. 18 (IBM Corporation, Somers, NY, USA), which was also used for data analysis.

Following review of the completed interviews by the research team in each country, a database with botanical composition data for all PFS products reported was compiled for each country and then merged into a single database. Potential product duplicates between countries were not removed. Each product was coded for its botanical ingredients in scientific, English and local names and botanicals were coded after removing duplicates between countries. Additionally, each product was categorised as a single- or multi-botanical product. To indicate the certainty of the matching of products, a series of numerical codes were used, based on those used in the National Health and Nutrition Examination Survey 2005--2006 [@pone.0092265-National2]. Values ranged from 1--5, where "1" indicated an exact match, "2" a probable match, "3" a reasonable match, "4" a default match and "5" no match. Only products with certainty values 1 to 4 have been included in the analyses.

Respondent data were recorded in a separate database. A number of variables were created and/or recoded to facilitate reporting and analysis, including: 1) "education level", defined as low, medium, and high; 2) "BMI", which was calculated from self-reported weight and height, and for which WHO criteria [@pone.0092265-World1] were used to categorise individuals as underweight (BMI\<18.5 kg/m^2^), normal weight (BMI 18.5-\<25 kg/m^2^), overweight (BMI 25-\<30 kg/m^2)^ and obese (BMI ≥30 kg/m^2^); 3) "physical activity", calculated using the short version of the IPAQ [@pone.0092265-Craig1] and defined as low, moderate or high.

Absolute frequencies and percentages for each of the variable categories were used to describe the qualitative nominal/ordinal and discrete quantitative survey data. In turn, all data have been stratified by gender, age range and country - also using absolute frequencies and percentages and 95% confidence intervals. When describing the association between two qualitative variables (nominal or ordinal), contingency tables were used. The continuous quantitative variables (e.g. BMI, alcohol) were recoded into categorical variables.

It is important to note that when reporting the main results of the survey, the unit of analysis varies depending on the variables used, i.e. for certain variables the unit is an individual respondent, however, given the potential intake of multiple supplements by one respondent, the unit of analysis may change to the supplement level. Furthermore, all results presented in the tables represent the analysis of raw data as opposed to data weighted by the population size. Data were not weighted because of the study methodology selected, whereby all country samples were very similar in size and included only PFS consumers.

Validation study {#s2g}
----------------

In order to validate the PFS usage questionnaire, a validation study was conducted in which the data collected using the survey instrument were compared with a 30 to 180-day diary (used as the gold standard). The study was conducted in two of the PlantLIBRA consumer survey cities: Las Palmas de Gran Canaria (Spain) and Milan (Italy), where 48 and 49 consumers respectively were recruited using convenience sampling. The PFS usage questionnaire was completed by the respondents at the beginning and at the end of the 6-month period of the validation; during this time the consumers also completed the usage diary. Data from the last questionnaire and the diary were compared for concordance, and results are shown in [Table 1](#pone-0092265-t001){ref-type="table"}, indicating a good agreement for product consumed, dose form and doses per day.

10.1371/journal.pone.0092265.t001

###### Validation study results.

![](pone.0092265.t001){#pone-0092265-t001-1}

  Variable                            Concordance[a](#nt101){ref-type="table-fn"}   Milan   Las Palmas de Gran Canaria       
  ---------------------------------- --------------------------------------------- ------- ---------------------------- ---- -------
  Product used                                            Yes                        47                95.9              48   100.0
                                                          No                          2                4.1               0     0.0
  Dose form (pills, capsules, etc)                        Yes                        45                91.8              47   97.9
                                                          No                          4                8.2               1     2.1
  Doses per day                                           Yes                        45                91.8              38   79.2
                                                          No                          4                8.2               10   20.8

Concordance between both methods: the PFS usage questionnaire and the 6-month usage diary.

Results {#s3}
=======

Characteristics of the PFS consumer sample {#s3a}
------------------------------------------

A final sample of 2359 consumers (those eligible and willing to participate) was recruited from 11783 screened individuals ([Table 2](#pone-0092265-t002){ref-type="table"}). Due to different legal frameworks (different distribution of botanicals in food supplements and medicinal products), more individuals had to be screened in Finland in order to recruit the required 400 consumers. [Table 2](#pone-0092265-t002){ref-type="table"} also shows the sample used for the estimation of the usage prevalence rate. The estimated weighted overall PFS usage prevalence rate was 18.8% and per-country rates were as follows: Finland 9.6%, Germany 16.9%, Italy 22.7%, Romania 17.6%, Spain 18.0% and the United Kingdom 19.1%.

10.1371/journal.pone.0092265.t002

###### Distribution of screened individuals, PFS consumers interviewed and prevalence sample by country and gender.

![](pone.0092265.t002){#pone-0092265-t002-2}

                                                                                                                                                   Finland   Germany   Italy   Romania   Spain   United Kingdom   Total
  ----------------------------------------------------------------------------------------- ------------------------------------------- --------- --------- --------- ------- --------- ------- ---------------- -------
  Total contacts (n)                                                                         Total individuals screened for the survey    Males     1405      1031      907      795      811         830         5779
                                                                                                                                         Females    1379      1028     1044      827      932         794         6004
                                                                                             Total PFS consumers interviewed accepted     Males      193       197      187      199      174         191         1141
                                                                                                                                         Females     208       201      191      201      228         189         1218
  Prevalence sample: systematically selected sample 1st three months of the Fieldwork (n)              Individuals screened               Males      486       564      439      502      551         454         2996
                                                                                                                                         Females     519       571      547      501      648         563         3349
                                                                                             PFS consumers among Individuals screened     Males      33        90       99       95       55           65          437
                                                                                                                                         Females     71        111      156      124      133         144          739
  PFS consumption prevalence (weighted) (%)                                                                                                          9.6      16.9     22.7     17.6     18.0         19.1        18.8

Survey respondents were recruited to fixed quotas for age and gender, which were achieved, with some differences within countries ([Table 3](#pone-0092265-t003){ref-type="table"}). In Finland the proportion of adults aged 50--59 years was significantly higher (26.2%), whilst the opposite was true in Italy, where consumers in that age group constituted only 13.0% of adults. Romania had a significantly higher number of consumers in the youngest age group (30.5%), in contrast to Spain and the United Kingdom, where this age group represented only 9.5% and 9.0% of adult consumers, respectively. A significantly higher proportion of female consumers were recruited in Spain (56.7%) and in the United Kingdom marginally more males were recruited (50.3%). Across all countries, more than half of the participants (57.5%) were employed ([Table 3](#pone-0092265-t003){ref-type="table"}), with the percentages slightly lower in Finland (50.9%) and in the United Kingdom (52.4%). The majority of participating consumers were educated to medium level ([Table 3](#pone-0092265-t003){ref-type="table"}).

10.1371/journal.pone.0092265.t003

###### PlantLIBRA\'s PFS consumer survey -- socio-demographic sample characteristics, overall and by country.

![](pone.0092265.t003){#pone-0092265-t003-3}

  Characteristics                               Categories                     All countries        Finland        Germany         Italy         Romania         Spain         United Kingdom                                                                                
  --------------------------- ----------------------------------------------- --------------- ------------------- --------- ------------------- --------- ------------------- ---------------- ------------------- ----- ------------------- ----- ------------------- ----- -------------------
  Gender                                           Male                            1141        48.4 (46.4--50.4)     193     48.1 (43.2--53.0)     197     49.5 (44.6--54.4)        187         49.5 (44.4--54.5)   199   49.8 (44.8--54.7)   174   43.3 (38.4--48.1)   191   50.3 (45.2--55.3)
                                                  Female                           1218        51.6 (49.6--53.7)     208     51.9 (47.0--56.8)     201     50.5 (45.6--55.4)        191         50.5 (45.5--55.6)   201   50.3 (45.3--55.2)   228   56.7 (51.9--61.6)   189   49.7 (44.7--54.8)
  Age                                          18--29 years                         418        17.7 (16.2--19.3)     63      15.7 (12.1--19.3)     77      19.4 (15.5--23.2)         84         22.2 (18.0--26.4)   122   30.5 (26.0--35.0)   38     9.5 (6.6--12.3)    34     9.0 (6.1--11.8)
                                               30--39 years                         445        18.9 (17.3--20.4)     65      16.2 (12.6--19.8)     57      14.3 (10.9--17.8)         88         23.3 (19.0-27.6)    65    16.3 (12.6--20.0)   101   25.1 (20.9--29.4)   69    18.2 (14.3--22.0)
                                               40--49 years                         460        19.5 (17.9--21.1)     64      16.0 (12.4--19.6)     82      20.6 (16.6--24.6)         63         16.7 (12.9--20.4)   46    11.5 (8.4--14.6)    88    21.9 (17.8--25.9)   117   30.8 (26.1--35.4)
                                               50--59 years                         441        18.7 (17.1--20.3)     105     26.2 (21.9--30.5)     80      20.1 (16.2--24.0)         49         13.0 (9.6--16.4)    67    16.8 (13.1--20.4)   76    18.9 (15.1--22.7)   64    16.8 (13.1--20.6)
                                                 ≥60 years                          595        25.2 (23.5--27.0)     104     25.9 (21.6--30.2)     102     25.6 (21.3--29.9)         94         24.9 (20.5--29.2)   100   25.0 (20.8--29.3)   99    24.6 (20.4--28.8)   96    25.3 (20.9--29.6)
  Education                                         Low                             249        10.6 (9.3--11.8)      47      11.7 (8.6--14.9)       3       0.8 (0.0--1.6)           72         19.1 (15.1--23.0)   35     8.8 (6.0--11.5)    92    22.9 (18.8--27.0)    0           --
                                                  Medium                           1549        65.7 (63.6--67.6)     237     59.1 (54.3--63.9)     329     82.7 (78.9--86.4)        222         58.7 (53.8--63.7)   190   47.5 (42.6--52.4)   256   63.7 (59.0--68.4)   315   82.9 (79.1--86.7)
                                                   High                             561        23.8 (22.1--25.5)     117     29.2 (24.7--33.6)     66      16.6 (12.9--20.2)         84         22.2 (18.0--26.4)   175   43.8 (38.9--48.6)   54    13.4 (10.1--16.8)   65    17.1 (13.3--20.9)
  Current employment status                      Employed                          1357        57.5 (55.5--59.5)     204     50.9 (46.0--55.8)     240     60.3 (55.5--65.1)        221         58.5 (53.5--63.4)   249   62.3 (57.5--67.0)   244   60.7 (55.9--65.5)   199   52.4 (47.3--57.4)
                               Other groups [a](#nt102){ref-type="table-fn"}       1002        42.5 (40.9--44.5)     197     49.1 (44.2--54.0)     158     39.7 (34.9--44.5)        157         41.5 (36.6--46.5)   151   37.8 (33.0--42.5)   181   39.3 (34.5--44.1)   181   47.6 (42.6--52.7)

Other groups: Unemployed; Housework; Student; Retired; Disabled; and Other.

Respondents were asked a number of questions regarding health-related lifestyle factors ([Table 4](#pone-0092265-t004){ref-type="table"}). Less than half of the consumers had never smoked (46.6%), less than one quarter were ex-smokers (23.1%) and less than one third were current smokers (30.3%).

10.1371/journal.pone.0092265.t004

###### PlantLIBRA\'s PFS consumer survey -- health-related lifestyle sample characteristics, overall and by country.

![](pone.0092265.t004){#pone-0092265-t004-4}

  Characteristics                                           Categories        All countries        Finland        Germany         Italy         Romania         Spain         United Kingdom                                                                                
  --------------------------------------------------- ---------------------- --------------- ------------------- --------- ------------------- --------- ------------------- ---------------- ------------------- ----- ------------------- ----- ------------------- ----- -------------------
  Regular use of non-PFS FS^ab^                                 No                1536        65.1 (63.2--67.0)     83      20.7 (16.7--24.7)     251     63.1 (58.3--67.8)        311         82.3 (78.4--86.1)   274   68.5 (63.9--73.1)   312   77.6 (73.5--81.7)   305   80.3 (76.3--84.3)
                                                               Yes                 767        32.5 (30.6--34.4)     306     76.3 (72.1--80.5)     122     30.7 (26.1--35.2)         63         16.7 (12.9--20.4)   112   28.0 (23.6--32.4)   89    22.1 (18.1--26.2)   75    19.7 (15.7--23.7)
                                                             Not sure              56          2.4 (1.8--3.0)       12       3.0 (1.3--4.7)       25       6.3 (3.9--8.7)           4           1.1 (0.1--2.1)     14     3.5 (1.7--5.3)      1     0.3 (0.0--0.7)      0           --
  Smoking habit                                            Never smoker           1100        46.6 (44.6--48.6)     182     45.4 (40.5--50.3)     183     46.0 (41.1--50.9)        181         47.9 (42.8--52.9)   214   53.5 (48.6--58.4)   177   44.0 (39.2--48.9)   163   42.9 (37.9--47.9)
                                                          Former smoker            544        23.1 (21.4--24.8)     129     32.2 (27.6--36.8)     81      20.4 (16.4--24.3)         85         22.5 (18.3--26.7)   57    14.3 (10.8--17.7)   94    23.4 (19.2--27.5)   98    25.8 (21.4--30.2)
                                                          Current smoker           715        30.3 (28.5--32.2)     90      22.4 (18.4--26.5)     134     33.7 (29.0--38.3)        112         29.6 (25.0--34.2)   129   32.3 (27.7--36.8)   131   32.6 (28.0--37.2)   119   31.3 (26.7--36.0)
  Self-reported health status                               Very good              353        15.0 (13.5--16.4)     81      20.2 (16.3--24.1)     49      12.3 (9.1--15.5)          22          5.8 (3.5--8.2)     80    20.0 (16.1--23.9)   49    12.2 (9.0--15.4)    72    19.0 (15.0--22.9)
                                                               Good               1427        60.5 (58.5--62.5)     225     56.1 (51.3--61.0)     220     55.3 (50.4--60.2)        243         64.3 (59.5--69.1)   245   61.3 (56.5--66.0)   258   64.2 (59.5--68.9)   236   62.1 (57.2--67.0)
                                                       Neither bad nor good        496        21.0 (19.4--22.7)     77      19.2 (15.3--23.1)     111     27.9 (23.5--32.3)        111         29.4 (24.8--34.0)   73    18.3 (14.5--22.0)   81    20.2 (16.2--24.1)   43    11.3 (8.1--14.5)
                                                               Bad                 70          3.0 (2.3--3.7)       16       4.0 (2.1--5.9)       18       4.5 (2.5--6.6)           2           0.5 (0.0--1.3)      2     0.5 (0.0--1.2)     14     3.5 (1.7--5.3)     18     4.7 (2.6--6.9)
                                                             Very bad              13          0.6 (0.3--0.9)        2      0.5 (0.0 -- 1.2)       0             --                 0                 --            0           --            0           --           11     2.9 (1.2--4.6)
  CAM[c](#nt105){ref-type="table-fn"} usage                    Yes                 947        40.1 (38.2--42.1)     223     55.6 (50.7--60.5)     204     51.3 (46.3--56.2)         96         25.4 (21.0--29.8)   77    19.3 (15.4--23.1)   319   79.4 (75.4--83.3)   28     7.4 (4.7--10.0)
                                                                No                1412        59.9 (57.9--61.8)     178     44.4 (39.5--49.3)     194     48.7 (43.8--53.7)        282         74.6 (70.2--79.0)   323   80.8 (76.9--84.6)   83    20.7 (16.7--24.6)   352   92.6 (90.0--95.3)
  Alcohol consumption                                    0-\<1 times/day          1398        59.3 (57.3--61.3)     281     70.1 (65.6--74.6)     245     61.6 (56.8--66.3)        116         30.7 (26.0--35.3)   232   58.0 (53.2--62.8)   291   72.4 (68.0--76.8)   233   61.3 (56.4--66.2)
                                                           ≥1 times/day            296        12.6 (11.2--13.9)     13       3.2 (1.5--5.0)       27       6.8 (4.3--9.3)          156         41.3 (36.3--46.2)    9     2.3 (0.8--3.7)     46    11.4 (8.3--14.6)    45    11.8 (8.6--15.1)
                                                             Not sure              614        26.0 (24.3--27.8)     107     26.7 (22.4--31.0)     126     31.7 (27.1--36.2)        106         28.0 (23.5--32.6)   159   39.8 (35.0--44.6)   65    16.2 (12.6--19.8)   102   26.8 (22.4--31.3)
  BMI[d](#nt106){ref-type="table-fn"} categories           Underweight             69          2.9 (2.4--3.6)        9       2.2 (0.8--3.7)        4       1.0 (0.0--2.0)           12          3.2 (1.4--4.9)     20     5.0 (2.9--7.1)      6      1.5 (.3--2.7)     18     4.7 (2.6--6.9)
                                                          Normal weight           1116        47.3 (45.3--49.3)     188     46.9 (42.0--51.8)     198     49.7 (44.8--54.7)        246         65.1 (60.3--69.9)   184   46.0 (41.1--50.9)   169   42.0 (37.2--46.9)   131   34.5 (29.7--39.3)
                                                            Overweight             818        34.7 (32.8--36.6)     147     36.7 (31.9--41.4)     159     40.0 (35.1--44.8)         98         25.9 (21.5--30.4)   142   35.5 (30.8--40.2)   155   38.6 (33.8--43.3)   117   30.8 (26.1--35.4)
                                                             Obesity               356        15.1 (13.7--16.5)     57      14.2 (10.8--17.6)     37       9.3 (6.4--12.2)          22          5.8 (3.5--8.2)     54    13.5 (10.2--16.9)   72    17.9 (14.2--21.7)   114   30.0 (25.4--34.6)
  Physical activity[e](#nt107){ref-type="table-fn"}            Low                 436        18.5 (16.9--20.1)     53      13.2 (9.9--16.5)      87      21.9 (17.8--25.9)        141         37.3 (32.4--42.2)    5     1.3 (0.2--2.3)     43    10.7 (7.7--13.7)    107   28.2 (23.6--32.7)
                                                             Moderate              909        38.5 (36.6--40.5)     156     38.9 (34.1--43.7)     139     34.9 (30.2--39.6)        191         50.5 (45.5--55.6)   53    13.3 (9.9--16.6)    234   58.2 (53.4--63.0)   136   35.8 (31.0--40.6)
                                                               High               1012        42.9 (40.9--44.9)     192     47.9 (43.0--52.8)     171     43.0 (38.1--47.8)         45         11.9 (8.6--15.2)    342   85.5 (82.1--89.0)   125   31.1 (26.6--35.6)   137   36.1 (31.2--40.9)

***Question asked*** **:** Other than PLANT FOOD SUPPLEMENT, have you taken any of the following supplements on a regular basis in the last 12 months? (mark all that apply). ***Possible responses***: Vitamins (A, B, D, E, etc.); Minerals (eg. potassium, calcium); Amino acids; Enzymes (eg. lactase); Prebiotics (eg. oligosaccharides, fibre); Probiotics (eg. bifidobacteria, yeasts); Fatty acids (eg. fish oil); Other.

FS =  Food supplements.

CAM = Complementary and Alternative Medicine, including: Acupuncturist; Chiropractor; Homeopath; Herbalist; Massage therapist; Traditional/faith healer; Reflexologist; Recognised treatment i.e. not \"alternative\"; Esoteric treatment; and "Cannot be classified".

BMI =  Body Mass Index; WHO categories [@pone.0092265-World1].

IPAQ categories [@pone.0092265-Craig1].

More than half of the total respondents (59.3%) had not consumed alcohol or had consumed it less than once daily; more than a tenth (12.6%) reported daily alcohol consumption.

The proportion of overweight and obese people in the survey was 49.8% ([Table 4](#pone-0092265-t004){ref-type="table"}). Some significant differences in levels of physical activity were noted between countries. High levels of activity were reported by 85.5% of Romanian respondents compared to a value of 42.9% across all countries.

Most of the respondents (65.1%) reported not being regular consumers of food supplements other than PFS in the preceding 12 months, except for Finland ([Table 4](#pone-0092265-t004){ref-type="table"}). The proportion of non-consumers varied from 20.7% in Finland to more than 80% in the United Kingdom and Italy. By contrast, in Finland 76.3% of the individuals were regular consumers of food supplements.

Over half of all respondents (59.5%) reported not having used CAM therapies/treatments in the past year. This is particularly the case in Italy (74.6%), Romania (80.8%) and the United Kingdom (92.6%).

Three quarters of consumers reported their health status as very good or good (75.5%), while 3.6% reported it as bad or very bad and 21.0% as neither bad nor good ([Table 4](#pone-0092265-t004){ref-type="table"}).

Between countries, more consumers reported their health status as very good or good in Romania (81.3%) and in the United Kingdom (81.1%) than in other countries; though conversely the highest proportion reporting their health status as bad or very bad was also in the United Kingdom (7.6%).

PFS usage patterns {#s3b}
------------------

Overall, products are most often taken "periodically" (37.3%) with respondents also reporting using PFS when experiencing a "flare up or worsening of a condition" (22.2%) ([Table 5](#pone-0092265-t005){ref-type="table"}). Products are also used on a more "sporadic basis" (19.8%) and on "other non-specified occasions" (17.8%). Both men and women reported taking products on a periodic basis (39.3%, 35.6%) and this was also true for both age groups ([Table 5](#pone-0092265-t005){ref-type="table"}). Periodic use was reported significantly more often in Finland (46.2%), Germany (50.7%), Italy (41.3%) and Romania (41.8%), but in Spain, "another reason" was most reported (46.0%) and in the United Kingdom, sporadic use (34.8%) was significantly higher than any other reason as to when products were used ([Table 6](#pone-0092265-t006){ref-type="table"}).

10.1371/journal.pone.0092265.t005

###### PlantLIBRA\'s PFS consumer survey -- PFS usage patterns, per product used by a respondent, overall and by gender and age group.

![](pone.0092265.t005){#pone-0092265-t005-5}

                                                                        Gender         Age group                                                                                
  -------------------------------------------------------- ------ ------------------- ----------- ------------------- ----- ------------------- ----- ------------------- ----- --------------------
  I took it whenever/sporadically                           568    19.8 (18.3--21.2)      280      20.6 (18.5--22.8)   288   19.0 (17.0--21.0)   437   20.5 (18.8--22.2)   131   17.6 (14.9--20.4)
  I take it periodically, during those times only           1072   37.3 (35.5--39.1)      533      39.3 (36.7--41.9)   539   35.6 (33.1--38.0)   827   38.8 (36.7--40.9)   245   33.0 (29.6--36.46)
  I took it when I had a flare up/worsening of condition    638    22.2 (20.7--23.7)      278      20.5 (18.3--22.6)   360   23.8 (21.6--25.9)   451   21.2 (19.4--22.9)   187   25.2 (22.1--28.3)
  Other reason                                              512    17.8 (16.4--19.2)      224      16.5 (14.5--18.5)   288   19.0 (17.0--21.0)   353   16.6 (15.0--18.1)   159   21.4 (18.5--24.4)
  Not sure                                                   84     2.9 (2.3--3.5)        43        3.2 (2.2--4.1)     41     2.7 (1.9--3.5)     63     3.0 (2.2--3.7)     21      2.8 (1.6--4.0)

***Questions asked.*** During the last 12 months, in what months have you taken this supplement? (mark all that apply). ***Possible responses***: Jan, Feb, Mar, Apr, May, June, July, Aug, Sep, Oct, Nov, Dec, All year round; Why did you decide to take this supplement in the months stated? (one answer only). ***Possible responses***: I took it whenever/sporadically; I take it periodically, during those times only; When I had a flare up/worsening of condition; Other reason; Not sure.

10.1371/journal.pone.0092265.t006

###### PlantLIBRA\'s PFS consumer survey -- PFS usage patterns, per product used by a respondent, overall and by country.

![](pone.0092265.t006){#pone-0092265-t006-6}

                                                            Finland (n = 665)   Germany (n = 446)   Italy (n = 417)   Romania (n = 464)   Spain (n = 465)   United Kingdom (n = 417)                                                            
  -------------------------------------------------------- ------------------- ------------------- ----------------- ------------------- ----------------- -------------------------- ----- ------------------- ----- ------------------- ----- -------------------
  I took it whenever/sporadically                                  83           12.5 (10.0--15.0)         102         22.9 (19.0--26.8)         73             17.5 (13.9--21.2)       60    12.9 (9.9--16.0)    105   22.6 (18.8--26.4)   145   34.8 (30.2--39.4)
  I take it periodically, during those times only                  307          46.2 (42.4--50.0)         226         50.7 (46.0--55.3)         172            41.3 (36.5--46.0)       194   41.8 (37.3--46.3)   68    14.6 (11.4--17.8)   105   25.2 (21.0--29.4)
  I took it when I had a flare up/worsening of condition           126          19.0 (16.0--21.9)         89          20.0 (16.2--23.7)         128            30.7 (26.3--35.1)       117   25.2 (21.3--29.2)   75    16.1 (12.8--19.5)   103   24.7 (20.6--28.8)
  Other reason                                                     140          21.1 (18.0--24.2)         26           5.8 (3.7--8.0)           32              7.7 (5.1--10.2)        51    11.0 (8.1--13.8)    214   46.0 (41.5--50.6)   49    11.8 (8.7--14.9)
  Not sure                                                          9            1.4 (0.5--2.2)            3           0.7 (0.0--1.4)           12               2.9 (1.3--4.5)        42     9.1 (6.4--11.7)     3     0.7 (0.0--1.4)     15     3.6 (1.8--5.4)

***Questions asked.*** During the last 12 months, in what months have you taken this supplement? (mark all that apply) ***Possible responses***: Jan, Feb, Mar, Apr, May, June, July, Aug, Sep, Oct, Nov, Dec, All year round; Why did you decide to take this supplement in the months stated? (one answer only) ***Possible responses***: I took it whenever/sporadically; I take it periodically, during those times only; When I had a flare up/worsening of condition; Other reason; Not sure.

PFS products used {#s3c}
-----------------

Respondents reported a total of 1288 products across the six countries. At individual country level, the highest numbers of different PFS were used in Italy (289) and Spain (284); in the United Kingdom, the number of different PFS was approximately half that of the other countries ([Table 7](#pone-0092265-t007){ref-type="table"}). The number of different botanical ingredients was 491, with the maximum number of different botanicals contained in a single product being 46 and present in a German product. The United Kingdom differed from the other countries as the products reported contained a lower number of botanical ingredients (maximum 8).

10.1371/journal.pone.0092265.t007

###### PlantLIBRA\'s PFS consumer survey -- Characteristics of PFS reported by respondents.

![](pone.0092265.t007){#pone-0092265-t007-7}

                                               Total   Finland   Germany   Italy   Romania   Spain   United Kingdom
  ------------------------------------------- ------- --------- --------- ------- --------- ------- ----------------
  Number of products                           1288      213       190      289      196      284         116
  Number of botanicals                          491      196       191      222      219      218          47
  Number of manufacturers                       449      69        99       106      61       97           17
  Maximum number of ingredients per product     46       23        46       20       39       30           8

In terms of the number of products used, 83.7% of all consumers reported taking one product in the preceding 12 months, with 12.3% taking two products and 4.0% using more than two products ([Table 8](#pone-0092265-t008){ref-type="table"}). Generally this pattern was similar for both men and women and across the age groups, although those over 60 did report a significantly higher use of two or more products than those under 60 (19.5% vs. 15.2%) ([Table 8](#pone-0092265-t008){ref-type="table"}). At country level ([Table 9](#pone-0092265-t009){ref-type="table"}), some significant differences were noted: in Finland, the percentage of consumers using two or more products was significantly higher than in all other countries (40.2%).

10.1371/journal.pone.0092265.t008

###### PlantLIBRA\'s PFS consumer survey -- number and type of products taken, overall distribution and by gender and age group.

![](pone.0092265.t008){#pone-0092265-t008-8}

                                                                      Total)        Gender         Age group                                                                                 
  -------------------------- --------------------------------------- -------- ------------------- ----------- ------------------- ----- ------------------- ------ ------------------- ----- -------------------
  Number of products taken                  1 product                  1975    83.7 (82.2--85.2)      980      85.9 (83.9--87.9)   995   81.7 (79.5--83.9)   1496   84.8 (83.1--86.5)   479   80.5 (77.3--83.7)
                                           2 products                  289     12.3 (10.9--13.6)      123      10.8 (9.0--12.6)    166   13.6 (11.7--15.6)   196    11.1 (9.6--12.6)    93    15.6 (12.7--18.6)
                                          \>2 products                  95      4.0 (3.2--4.8)        38        3.3 (2.3--4.4)     57     4.7 (3.5--5.9)      72     4.1 (3.2--5.0)     23     3.9 (2.3--5.4)
  Product type                         1 single-botanical              1214    51.5 (49.5--53.5)      606      53.1 (50.2--56.0)   608   49.9 (47.1--52.7)   900    51.0 (48.7--53.4)   314   52.8 (48.8--56.8)
                                       1 multi -botanical              761     32.3 (30.4--34.2)      374      32.8 (30.1--35.5)   387   31.8 (29.2--34.4)   596    33.8 (31.6--36.0)   165   27.7 (24.1--31.3)
                                   2 or more single-botanical          104      4.4 (3.6--5.2)        45        3.9 (2.8--5.1)     59     4.8 (3.6--6.1)      72     4.1 (3.2--5.0)     32     5.4 (3.6--7.2)
                              2 or more single- and multi-botanical    280     11.9 (10.6--13.2)      116      10.2 (8.4--11.9)    164   13.5 (11.6--15.4)   196    11.1 (9.6--12.6)    84    14.1 (11.3--16.9)

10.1371/journal.pone.0092265.t009

###### PlantLIBRA\'s PFS consumer survey -- number and type of products taken, by country.

![](pone.0092265.t009){#pone-0092265-t009-9}

                                                                      Finland (n = 401)   Germany (n = 398)   Italy (n = 378)   Romania (n = 400)   Spain (n = 402)   United Kingdom (n = 380)                                                            
  -------------------------- --------------------------------------- ------------------- ------------------- ----------------- ------------------- ----------------- -------------------------- ----- ------------------- ----- ------------------- ----- -------------------
  Number of products taken                  1 product                        240          59.9 (55.1--64.7)         351         88.2 (85.0--91.4)         341            90.2 (87.2--93.2)       350   87.5 (84.3--90.8)   345   85.8 (82.4--89.2)   348   91.6 (88.8--94.4)
                                           2 products                        93           23.2 (19.1--27.3)         45          11.3 (8.2--14.4)          34              9.0 (6.1--11.9)        40    10.0 (7.1--12.9)    48    11.9 (8.8--15.1)    29     7.6 (5.0--10.3)
                                          \>2 products                       68           17.0 (13.3--20.6)          2           0.5 (0.0--1.2)            3               0.8 (0.0--1.7)        10     2.5 (1.0--4.0)      9     2.2 (0.8--3.7)      3     0.8 (0.0--1.7)
  Product type                         1 single-botanical                    82           20.5 (16.5--24.4)         172         43.2 (38.3--48.1)         176            46.6 (41.5--51.6)       251   62.8 (58.0--67.5)   212   52.7 (47.9--57.6)   321   84.5 (80.8--88.1)
                                       1 multi -botanical                    158          39.4 (34.6--44.2)         179         45.0 (40.1--49.9)         165            43.7 (38.6--48.7)       99    24.8 (20.5--29.0)   133   33.1 (28.5--37.7)   27     7.1 (4.5--9.7)
                                   2 or more single-botanical                 8            2.0 (0.6--3.4)           12           3.0 (1.3--4.7)           13               3.4 (1.6--5.3)        20     5.0 (2.9--7.1)     26     6.5 (4.1--8.9)     25     6.6 (4.1--9.1)
                              2 or more single- and multi-botanical          153          38.2 (33.4--42.9)         35           8.8 (6.0--11.6)          24               6.4 (3.9--8.8)        30    7.5 (4.92--10.1)    31     7.7 (5.1--10.3)     7     1.8 (0.5--3.2)

Overall 51.5% of consumers used a single-botanical product and 32.3% used one multi-botanical product ([Table 8](#pone-0092265-t008){ref-type="table"}). There were no significant differences between males and females in this usage pattern, but consumers aged over 60 used less multi-botanical products than those aged 18--59 (27.7% and 33.8% respectively) ([Table 8](#pone-0092265-t008){ref-type="table"}). Overall, fewer consumers reported using two or more single-botanical products (4.4%) and two or more single- and multi-botanical products (11.9%) ([Table 8](#pone-0092265-t008){ref-type="table"}).

There were some significant differences across countries in the type of products consumed ([Table 9](#pone-0092265-t009){ref-type="table"}). In the six countries, the values for single-botanical products range from 84.5% (the United Kingdom) to 20.5% (Finland). Usage of multi-botanical products was reported in all countries, with the lowest proportion (7.1%) reported in the United Kingdom ([Table 9](#pone-0092265-t009){ref-type="table"}). The use of two or more single-botanical products was low in all countries as was the usage of two or more single- and multi-botanical products. Finland was an exception to the latter, with 38.2% of respondents taking multiple products ([Table 9](#pone-0092265-t009){ref-type="table"}).

The most common dose forms used ([Table 10](#pone-0092265-t010){ref-type="table"}) are capsules (38.3%) and pills/tablets/lozenges (36.8%). No significant difference was observed in relation to gender or age ([Table 10](#pone-0092265-t010){ref-type="table"}). Across the six countries ([Table 11](#pone-0092265-t011){ref-type="table"}), solid forms are generally most popular, although capsules were used less frequently in Romania (17.7%). Liquid forms were less common in the United Kingdom (8.2%) and Germany (9.9%), but more common in Finland (26.2%) and Italy (26.4%) ([Table 11](#pone-0092265-t011){ref-type="table"}).

10.1371/journal.pone.0092265.t010

###### PlantLIBRA\'s PFS consumer survey -- PFS dose forms used, per product used by a respondent, overall and by gender and age group.

![](pone.0092265.t010){#pone-0092265-t010-10}

  Dose forms                Total        Gender         Age group                                                                                
  ------------------------ ------- ------------------- ----------- ------------------- ----- ------------------- ----- ------------------- ----- -------------------
  Capsules^a^               1101    38.3 (36.5--40.1)      522      38.4 (35.9--41.0)   579   38.2 (35.8--40.6)   844   39.6 (37.5--41.7)   257   34.6 (31.2--38.0)
  Pills/tablets/lozenges    1057    36.8 (35.0--38.5)      498      36.7 (34.1--39.2)   559   36.9 (34.4--39.3)   765   35.9 (33.8--37.9)   292   39.3 (35.8--42.8)
  Liquid^b^                  513    17.9 (16.5--19.3)      238      17.5 (15.5--19.6)   275   18.1 (16.2--20.1)   374   17.6 (15.9--19.2)   139   18.7 (15.9--21.5)
  Ampoules                   104     3.6 (2.9--4.3)        53        3.9 (2.9--4.9)     51     3.4 (2.5--4.3)     75     3.5 (2.7--4.3)     29     3.9 (2.5--5.3)
  Other^c^                   99      3.4 (2.8--4.1)        47        3.5 (2.5--4.4)     52     3.4 (2.5--4.4)     73     3.4 (2.7--4.2)     26     3.5 (2.2--4.8)

***Question asked***. And in which form do you usually take it? (mark the applicable form). *Possible responses*: Pills/tablets/lozenges; Softgel capsules/pearls; Hard capsules; Liquid (extract/syrup/drops); Sachets/packets; Ampoules; Other (specify); Not sure.

Capsules: s°ftgels/pearls/hard capsules.

Liquid: extract/syrups/dr°ps.

Other: P°wders, Sachets/Packets, Bars and "Not sure".

10.1371/journal.pone.0092265.t011

###### PlantLIBRA\'s PFS consumer survey -- PFS dose forms, per product used by a respondent, by country.

![](pone.0092265.t011){#pone-0092265-t011-11}

  Dose forms                                  Finland (n = 665)   Germany (n = 446)   Italy (n = 417)   Romania (n = 464)   Spain (n = 465)   United Kingdom (n = 417)                                                            
  ------------------------------------------ ------------------- ------------------- ----------------- ------------------- ----------------- -------------------------- ----- ------------------- ----- ------------------- ----- -------------------
  Capsules[a](#nt115){ref-type="table-fn"}           206          31.0 (27.5--34.5)         225         50.5 (45.8--55.1)         144            34.5 (30.0--39.1)       82    17.7 (14.2--21.2)   250   53.8 (49.2--58.3)   194   46.5 (41.7--51.3)
  Pills/tablets/lozenges                             261          39.3 (35.5--43.0)         154         34.5 (30.1--39.0)         126            30.2 (25.8--34.6)       234   50.4 (45.9--55.0)   98    21.1 (17.4--24.8)   184   44.1 (39.4--48.9)
  Liquid[b](#nt116){ref-type="table-fn"}             174          26.2 (22.8--29.5)         44           9.9 (7.1--12.6)          110            26.4 (22.1--30.6)       82    17.7 (14.2-21.2)    69    14.8 (11.6--18.1)   34     8.2 (5.5--10.8)
  Ampoules                                            0                  \-                  0                 \-                 13               3.1 (1.5--4.8)        47    10.1 (7.4--12.9)    44     9.5 (6.8--12.1)     0           --
  Other[c](#nt117){ref-type="table-fn"}              24            3.6 (2.2--5.0)           23           5.2 (3.1--7.2)           24               5.8 (3.5--8.0)        19     4.1 (2.3--5.9)      4     0.9 (0.1--1.7)      5     1.2 (0.2--2.2)

***Question asked***. And in which form do you usually take it? (mark the applicable form). *Possible responses*: Pills/tablets/lozenges; Softgel capsules/pearls; Hard capsules; Liquid (extract/syrup/drops); Sachets/packets; Ampoules; Other (specify); Not sure.

Capsules: softgels/pearls/hard capsules.

Liquid: extract/syrups/drops.

Other: Powders, Sachets/Packets, Bars and "Not sure".

Botanicals used {#s3d}
---------------

A total of 491 botanicals -used in at least one PFS- were reported across the six participating countries. An overview of all the reported botanicals -clustered by intervals of frequency of intake (number of consumers ranging from 194 to 5)- is shown in [Table 12](#pone-0092265-t012){ref-type="table"}. Based on the survey results, the eleven most frequently used botanicals (numbers of consumers ranging from 194 to 100) in descending order are *Ginkgo biloba* (ginkgo), *Oenothera biennis* (evening primrose), *Cynara scolymus* (artichoke), *Panax ginseng* (ginseng), *Aloe vera* (aloe), *Foeniculum vulgare* (fennel), *Valeriana officinalis* (valerian), *Glycine max* (soybean), *Melissa officinalis* (lemon balm), *Echinacea purpurea* (echinacea) and *Vaccinium myrtillus* (blueberry) ([Table 12](#pone-0092265-t012){ref-type="table"}).

10.1371/journal.pone.0092265.t012

###### PlantLIBRA\'s PFS consumer survey -- botanicals used by at least 5 respondents, ordered by the \"n of respondents".

![](pone.0092265.t012){#pone-0092265-t012-12}

  Used by n≥75 respondents          Used by n≥40-\<75 respondents         Used by n ≥20-\<40 respondents            Used by n≥5-\<20 respondents                                                                                                                                                            
  -------------------------- ------------------------------------------- -------------------------------- ------------------------------------------------ ---- -------------------------------------------------------------------------------------------------------------------------------------- ---- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  194                            *Ginkgo biloba; Oenothera biennis*                     74                              *Glycyrrhiza glabra*                38                                                    *Cichorium intybus; Malus pumila*                                                     19                                                                                                                                                            *Achillea millefolium; Arctium lappa; Centella asiatica; Punica granatum; Raphanus sativus; Pyrus communis*
  177                                     *Cynara scolymus*                             72                      *Mentha piperita; Paullinia cupana*         37                                                             *Curcuma longa*                                                              18                                                                                                                                                                                              *Artemisia absinthium; Pollen; Lecithin*
  170                                      *Panax ginseng*                              71                               *Malpighia glabra*                 36                                                             *Ananas comosus*                                                             17                                                                                                                                                                                      *Betula pubescens; Spirulina spec.; Vegetable charcoal;*
  145                                        *Aloe vera*                                70                               *Oenothera spec.*                  35                                                      *Daucus carota; Glycine spec.*                                                      16                                                                                                                                                                                      *Origanum majorana; Ruscus aculeatus;Terminalia chebula*
  131                                 *Foeniculum vulgare ssp*                          69                               *Silybum marianum*                 34                                                           *Myristica fragrans*                                                           15                                                                                                                                                               *Citrus paradise; Eschscholzia californica; Medicago sativa; Picea spec.; Vaccinium oxycoccus; Inulin*
  128                                  *Valeriana officinalis*                          66                     *Citrus limon; Matricaria chamomilla*        33                                *Crataegus monogyna; Cucurbita spec.; Dianthus spec.; Monascus purpureus*                                 14                                                                                                                                                *Althaea officinalis; Cuminum cyminum; Eryngium planum; Laminaria digitata; Rhamnus purshianus; Trigonella foenum-graecum; Zea mays*
  103                            *Glycine max; Melissa officinalis*                     64                                *Urtica dioica*                   32                                              *Petroselinum crispum; Vaccinium macrocarpon*                                               13                                                                                      *Chelidonium majus; Dioscorea villosa; Gossypium spec.; Hyssopus officinalis; Lactuca sativa; Origanum vulgare; Orthosiphon stamineus; Piper nigrum; Theobroma cacao; Trifolium pratense; Uncaria tomentosa; Lycopene; Equisetum spec.; Valeriana spec.*
  102                                   *Echinacea purpurea*                            63                               *Thymus vulgaris*                  31                               *Coriandrum sativum; Echinaca spec.; Elettaria cardamomum; Prunus domestica*                               12                                                                                                                                     *Asparagus officinalis; Azadirachta indica; Cassia occidentalis; Eucalyptus globulus; Tagetes erecta; Mentha spec.; Smilax officinalis; Xanthium spinosum*
  100                                  *Vaccinium myrtillus;*                           61                              *Salvia officinalis*                30                                                  *Cymbopogon citratus; Rhodiola rosea;*                                                  11                                                                                                    *Abies alba; Artemisia abrotanum; Cetraria islandica; Cinnamomum camphora; Ilex paraguariensis; Laurus nobilis; Nasturtium officinale; Salix alba; Tilia spec.; Fraxinus excelsior; Gentiana asclepiadea; Triticum aestivum*
  89                          *Camellia sinensis; Zingiber officinale*                  60                     *Cassia senna; Rosmarinus officinalis*       29                                                         *Calendula officinalis*                                                          10                          *Aegle marmelos; Aquilegia spec.; Armoracia rusticana; Brassica oleracea ssp.; Cheilocostus speciosus; Kaempferia galangal; Lepidium meyenii; Pimenta dioica; Populus nigra; Potentilla aurea; Santalum spec.; Sida cordifolia; Terminalia arjuna; Thymus serpyllum; Rubus fruticosus; Carlina acaulis; Centaurium spec.; Ganoderma lucidum; Tamarix gallica; Ceratonia siliqua*
  88                                     *Pimpinella anisum*                            59                 *Hypericum perforatum; Lavandula angustifolia*   28   *Eleutherococcus senticosus; Fucus vesiculosus; Plantago ovate; Solanum lycopersicum; Spirulina platensis; Saccharomyces cerevisiae*   9                                                                                        *Aesculus hippocastanum; Aloe ferox; Berberis aristata; Brassica oleracea var. botrytis; Capparis spinosa; Capsicum annuum var. annuum; Hieracium pilosella; Opuntia ficus-indica; Serenoa repens; Solanum nigrum; Tribulus terrestris; Melissa spec.*
  87                                      *Vitis vinifera*                              58                                 *Carum carvi*                    27                                                            *Citrus aurantium*                                                            8                                                               *Allium cepa; Apium graveolens; Boswellia serrate; Coffea spec.; Euterpe oleracea; Fumaria officinalis; Griffonia simplicifolia; Illicium verum; Malva sylvestris; Prunus armeniaca; Raphanus sativus convar. Sativus; Solidago virgaurea; Tamarindus indica; Carotene; Garcinia cambogia; Soy lecithin*
  81                                   *Taraxacum officinale*                           53                                 *Ribes nigrum*                   26                                         *Schisandra chinensis; Flavonoids; Syzygium aromaticum*                                          7                                                                                               *Acorus calamus; Angelica sinensis; Ascophyllum nodosum; Elymus repens; Ficus carica; Hamamelis virginiana; Phaseolus vulgaris; Prunus persica; Rheum spec.; Lutein; Capsicum annuum; Fraxinus spec.; Chamomile Eng; Violeta tricolor;*
  79                                  *Echinacea angustifolia*                          52                                *Oryza sativa;*                   25          *Angelica archangelica; Beta vulgaris ssp.vulgaris var. conditiva; Citrus sinensis; Juniperus communis; Peumus boldus*          6    *Brassica nigra; Brassica oleracea convar. acephala; Capsicum frutescens; Carthamus tinctorius; Cordyceps sinensis; Dioscorea spec.; Drosera rotundifolia; Echinacea pallida; Emblica officinalis; Fallopia japonica; Hedera spec.; Nigella sativa; Plantago psyllium; Satureja hortensis; Tilia platyphyllos; Hibiscus rosa-sinensis; Cirsium spec.; Fragaria spec.; Viola tricolor; Lavandula spec.; Fructooligosaccharides*
  78                           *Allium sativum Passiflora incarnata;*                   48                             *Hippophae rhamnoides*               23                *Borago officinalis; Gentiana lutea; Helianthus annuus; Ocimum basilicum; Panicum miliaceum; Pinus spec.*                 5                                                        *Aloe spec.; Alpinia galanga; Chamaemelum nobile; Coffea arabica; Cola acuminata; Cyamopsis tetragonoloba; Equisetum telmateia; Fagopyrum esculentum; Hibiscus sabdariffa; Pinus pinaster; Pinus sylvestris; Thymus spec.; Undaria pinnatifida; Withania somnifera; Isoflavones; Arecaceae spec.; Fallopia multiflora*
  77                                    *Linum usitatissimum*                           46                                *Triticum spec.*                  22                                      *Plantago lanceolata; Rhamnus frangula; Vaccinium vitis-idaea*                                          
  76                                     *Equisetum arvense*                            43                        *Rosa canina; Cinnamomum spec.*           21    *Carica papaya; Cinnamomum verum; Crataegus spec.; Hordeum vulgare; Polygonum aviculare; Saccharum officinarum; Spinacia oleracea*        
  75                          *Harpagophytum procumbens; Olea europaea*                 42                                *Sambucus nigra*                  20                                *Algae; Avena sativa; Betula spec.; Fiilipendula ulmaria; Humulus lupulus*                                    

[Table 13](#pone-0092265-t013){ref-type="table"} shows the overall unweighted ranking of botanicals, 1--40, according to the number of consumers, in decreasing order. [Table 13](#pone-0092265-t013){ref-type="table"} also shows that when unweighted overall data are stratified by gender, only slight differences between men and women become evident and only *Glycine max* (soybean) was used significantly more by women than by men ([Table 13](#pone-0092265-t013){ref-type="table"}).

10.1371/journal.pone.0092265.t013

###### PlantLIBRA\'s PFS consumer survey -- distribution of the overall top-40 botanicals\' reported consumption and the ranking of these botanicals when stratified by gender and age group.

![](pone.0092265.t013){#pone-0092265-t013-13}

                                All consumers   Gender     Age group                                                                                                     
  ---------------------------- --------------- -------- ---------------- ---- ----- ----------------- ---- ----- ----------------- ---- ----- ---------------- ---- ---- -----------------
  *Ginkgo biloba*                     1          194     8.2 (7.1--9.3)   1    107   9.4 (7.7--11.0)   3    87    7.1 (5.7--8.6)    2    135   7.7 (6.4--8.9)   1    59   9.9 (7.5--12.3)
  *Oenothera biennis*                 2          194     8.2 (7.1--9.3)   3    85    7.5 (5.9--8.9)    1    109   9.0 (7.4--10.5)   1    145   8.2 (6.9--9.5)   2    49   8.2 (6.0--10.4)
  *Cynara scolymus*                   3          173     7.3 (6.3--8.4)   5    73    6.4 (5.0--7.8)    2    100   8.2 (6.7--9.7)    4    128   7.3 (6.1--8.4)   4    45   7.6 (5.4--9.6)
  *Panax ginseng*                     4          167     7.1 (6.0--8.1)   2    94    8.2 (6.6--9.8)    5    73    6.0 (4.7--7.3)    3    133   7.5 (6.3--8.7)   6    34   5.7 (3.9--7.5)
  *Aloe vera*                         5          145     6.2 (5.2--7.1)   4    80    7.0 (5.5--8.5)    7    65    5.3 (4.1--6.6)    5    99    5.6 (4.5--6.7)   3    46   7.7 (5.6--9.8)
  *Foeniculum vulgare ssp.*           6          132     5.6 (4.7--6.5)   7    59    5.2 (3.9--6.4)    4    73    6.0 (4.7--7.3)    6    99    5.6 (4.5--6.7)   7    33   5.6 (3.7--7.3)
  *Valeriana officinalis*             7          125     5.3 (4.4--6.2)   6    62    5.4 (4.1--6.7)    8    63    5.2 (3.9--6.4)    7    97    5.5 (4.4--6.5)   9    28    4.7 (3.0--6.4
  *Glycine max*                       8          103     4.4 (3.5--5.2)   24   34    3.0 (2.0--3.9)    6    69    5.7 (4.4--6.9)    10   81    4.6 (3.6--5.5)   14   22   3.7 (2.2--5.2)
  *Melissa officinalis*               9          103     4.4 (3.5--5.2)   8    53    4.7 (3.4--5.8)    10   50    4.1 (3.0--5.2)    9    82    4.7 (3.7--5.6)   17   21   3.5 (2.1--5.0)
  *Echinacea purpurea*               10          102     4.3 (3.5--5.1)   12   43    3.8 (2.7--4.8)    9    59    4.8 (3.6--6.0)    8    83    4.7 (3.7--5.7)   21   19   3.2 (1.8--4.6)
  *Vaccinium myrtillus*              11          100     4.2 (3.4--5.1)   9    53    4.7 (3.4--5.8)    13   47    3.9 (2.8--4.9)    12   71    4.0 (3.1--4.9)   8    29   4.9 (3.1--6.6)
  *Pimpinella anisum*                12           89     3.8 (3.0--4.5)   11   47    4.1 (3.0--5.2)    21   42    3.5 (2.4--4.4)    16   65    3.7 (2.8--4.5)   11   24   4.0 (2.5--5.6)
  *Zingiber officinale*              13           89     3.8 (3.0--4.5)   10   53    4.7 (3.4--5.8)    29   36    3.0 (2.0--3.9)    15   66    3.7 (2.9--4.6)   13   23   3.9 (2.3--5.4)
  *Camellia sinensis*                14           87     3.7 (2.9--4.5)   17   39    3.4 (2.4--4.4)    11   48    3.9 (2.9--5.0)    11   72    4.1 (3.2--5.0)   33   15   2.5 (1.3--3.7)
  *Vitis vinifera*                   15           87     3.7 (2.9--4.5)   16   41    3.6 (2.5--4.6)    15   46    3.8 (2.7--4.8)    13   71    4.0 (3.1--4.9)   32   16   2.7 (1.4--4.0)
  *Taraxacum officinale*             16           80     3.4 (2.7--4.1)   21   36    3.2 (2.1--4.1)    17   44    3.6 (2.6--4.6)    17   65    3.7 (2.8--4.5)   34   15   2.5 (1.3--3.7)
  *Echinacea angustifolia*           17           79     3.4 (2.6--4.1)   23   34    3.0 (2.0--3.9)    16   45    3.7 (2.6--4.7)    20   60    3.4 (2.6--4.2)   20   19   3.2 (1.8--4.6)
  *Passiflora incarnata*             18           78     3.3 (2.6--4.0)   30   30    2.6 (1.7--3.5)    12   48    3.9 (2.9--5.0)    19   61    3.5 (2.6--4.3)   30   17   2.9 (1.5--4.2)
  *Linum usitatissimum*              19           77     3.3 (2.6--4.0)   13   43    3.8 (2.7--4.8)    33   34    2.8 (1.9--3.7)    22   56    3.2 (2.4--4.0)   16   21   3.5 (2.1--5.0)
  *Equisetum arvense*                20           76     3.2 (2.5--3.9)   19   37    3.2 (2.2--4.2)    23   39    3.2 (2.2--4.2)    23   55    3.1 (2.3--3.9)   15   21   3.5 (2.1--5.0)
  *Allium sativum*                   21           75     3.2 (2.5--3.9)   28   32    2.8 (1.9--3.7)    18   43    3.5 (2.5--4.5)    29   50    2.8 (2.1--3.6)   10   25   4.2 (2.6--5.8)
  *Harpagophytum procumbens*         22           75     3.2 (2.5--3.9)   18   39    3.4 (2.4--4.4)    26   36    3.0 (2.0--3.9)    40   40    2.3 (1.6--2.9)   5    35   5.9 (4.0--7.7)
  *Olea europaea*                    23           75     3.2 (2.5--3.9)   27   33    2.9 (1.9--3.8)    20   42    3.5 (2.4--4.4)    24   55    3.1 (2.3--3.9)   19   20   3.4 (1.9--4.8)
  *Glycyrrhiza glabra*               24           74     3.1 (2.4--3.8)   26   33    2.9 (1.9--3.8)    22   41    3.4 (2.4--4.4)    25   54    3.1 (2.3--3.8)   18   20   3.4 (1.9--4.8)
  *Mentha piperita*                  25           72     3.1 (2.4--3.8)   20   36    3.2 (2.1--4.1)    27   36    3.0 (2.0--3.9)    27   53    3.0 (2.2--3.8)   22   19   3.2 (1.8--4.6)
  *Paullinia cupana*                 26           72     3.1 (2.4--3.8)   14   43    3.8 (2.7--4.8)    38   29    2.4 (1.5--3.2)    14   66    3.7 (2.9--4.6)   74   6    1.0 (0.2--1.8)
  *Malpighia glabra*                 27           71     3.0 (2.3--3.7)   15   41    3.6 (2.5--4.6)    37   30    2.5 (1.6--3.3)    18   61    3.5 (2.6--4.3)   51   10   1.7 (0.7--2.7)
  *Oenothera spec*                   28           70     3.0 (2.3--3.7)   41   23    2.0 (1.2--2.8)    14   47    3.9 (2.8--4.9)    21   59    3.3 (2.5--4.2)   47   11   1.9 (0.8--2.9)
  *Silybum marianum*                 29           69     2.9 (2.2--3.6)   25   34    3.0 (2.0--3.9)    30   35    2.9 (1.9--3.8)    32   46    2.6 (1.9--3.3)   12   23   3.9 (2.3--5.4)
  *Matricaria chamomilla*            30           67     2.8 (2.2--3.5)   34   29    2.5 (1.6--3.4)    25   38    3.1 (2.1--4.1)    26   54    3.1 (2.3--3.8)   38   13   2.2 (1.0--3.3)
  *Citrus limon*                     31           66     2.8 (2.1--3.5)   37   24    2.1 (1.3--2.9)    19   42    3.5 (2.4--4.4)    30   48    2.7 (2.0--3.5)   25   18   3.0 (1.7--4.4)
  *Urtica dioica*                    32           64     2.7 (2.1--3.4)   31   30    2.6 (1.7--3.5)    34   34    2.8 (1.9--3.7)    28   51    2.9 (2.1--3.7)   37   13   2.2 (1.0--3.3)
  *Thymus vulgaris*                  33           63     2.7 (2.0--3.3)   36   28    2.5 (1.6--3.3)    31   35    2.9 (1.9--3.8)    33   44    2.5 (1.8--3.2)   24   19   3.2 (1.8--4.6)
  *Salvia officinalis*               34           61     2.6 (2.0--3.2)   32   22    1.9 (1.1--2.7)    35   39    3.2 (2.2--4.2)    34   43    2.4 (1.7--3.1)   29   18   3.0 (1.7--4.4)
  *Cassia senna*                     35           60     2.5 (1.9--3.2)   43   29    2.5 (1.6--3.4)    24   31    2.6 (1.7--3.4)    37   43    2.4 (1.7--3.1)   28   17   2.9 (1.5--4.2)
  *Rosmarinus officinalis*           36           60     2.5 (1.9--3.2)   38   24    2.1 (1.3--2.9)    28   36    3.0 (2.0--3.9)    39   41    2.3 (1.6--3.0)   23   19   3.2 (1.8--4.6)
  *Carum carvi*                      37           59     2.5 (1.9--3.1)   22   35    3.1 (2.1--4.0)    43   24    2.0 (1.2--2.7)    31   46    2.6 (1.9--3.3)   36   13   2.2 (1.0--3.3)
  *Hypericum perforatum*             38           59     2.5 (1.9--3.1)   29   31    2.7 (1.8--3.6)    39   28    2.3 (1.5--3.1)    35   43    2.4 (1.7--3.1)   31   16   2.7 (1.4--4.0)
  *Lavandula angustifolia*           39           57     2.4 (1.8--3.0)   40   23    2.0 (1.2--2.8)    32   34    2.8 (1.9--3.7)    36   43    2.4 (1.7--3.1)   35   14   2.4 (1.1--3.5)
  *Ribes nigrum*                     40           53     2.3 (1.7--2.8)   42   22    1.9 (1.1--2.7)    36   31    2.6 (1.7--3.4)    38   41    2.3 (1.6--3.0)   41   12   2.0 (0.9--3.1)

Products ordered according to the consumer distribution of the overall top-40 used botanicals (unweighted ranking).

Ranks show the shifts of the botanicals in the position of the overall 1--40 unweighted ranking when stratified by gender and age group.

When the overall top-40 botanical data are stratified by age groups, slight differences become evident. In the group of 18--59 year-olds, the most frequently used botanicals comply with the overall data just differing in the ranking, with *Oenothera biennis* (evening primrose) being the most frequently used botanical ([Table 13](#pone-0092265-t013){ref-type="table"}). In the group of 60+ year-old a stronger shift can be observed ([Table 13](#pone-0092265-t013){ref-type="table"}). Although *Ginkgo biloba* (ginkgo) is still the most reported botanical -as in the overall ranking- other botanicals are frequently used by that age group. *Harpagophytum procumbens* (devil\'s claw), *Vaccinium myrtillus* (blueberry) and *Allium sativum* (garlic) are within the most frequently reported botanicals, whereas *Glycine max* (soybean), *Melissa officinalis* (lemon balm) and *Echinacea purpurea* (echinacea) do not appear in the top 10 ranking.

Cross-country differences emerge when considering the overall top-40 botanicals more frequently present in PFS products in each of the individual six countries ([Table 14](#pone-0092265-t014){ref-type="table"}). In the Finnish sample, products containing *Glycine max* (soybean) are the most frequently used, followed by those containing *Echinacea angustifolia and purpurea* (echinacea). German consumers reported *Ginkgo biloba* (ginkgo), *Cynara scolymus* (artichoke) and *Olea europea* (olive) as the most frequently used botanicals; whilst in Romania, *Ginkgo biloba* (ginkgo) was also the ingredient most frequently indicated, followed by *Aloe vera* (aloe) and *Panax ginseng* (ginseng). Amongst Italian consumers, *Aloe vera* (aloe) was the most frequently used botanical, followed by *Foeniculum vulgare* (fennel) and *Valeriana officinalis* (valerian). In Spain, PFS containing *Cynara scolymus* (artichoke) were the most frequently used products, followed by those containing *Valeriana officinalis* (valerian) and *Equisetum arvense* (horsetail). In the United Kingdom, *Oenothera biennis* (evening primrose) was by far the most frequently reported botanical ingredient, followed by *Panax ginseng* (ginseng) and *Hypericum perforatum* (St. John\'s wort). In addition, there is a great variation in the ranking of consumed botanicals among countries.

10.1371/journal.pone.0092265.t014

###### PlantLIBRA\'s PFS consumer survey -- ranking of the overall top-40 botanicals\' reported consumption when stratified by country.

![](pone.0092265.t014){#pone-0092265-t014-14}

  Botanicals                    Finland   Germany         Italy         Romania   Spain    United Kingdom                                                                                                           
  ---------------------------- --------- --------- ------------------- --------- ------- ------------------ ----- ---- ------------------ ----- ----- ------------------- ----- ---- ------------------- ---- ----- -------------------
  *Ginkgo biloba*                            0             \-              1       50     12.6 (9.3--15.8)   12    17    4.5 (2.4--6.6)     1    105   26.3 (21.9--30.6)   27    11    2.7 (1.1--4.3)     11   11     2.9 (1.2--4.6)
  *Oenothera biennis*                        0             \-             22       15      3.8 (1.9--5.6)    174   1     0.3 (0.0--0.8)    164    1     0.3 (0.0--0.7)     20    13    3.2 (1.5--5.0)     1    164   43.2 (38.2--48.1)
  *Cynara scolymus*               53        12       3.0 (1.3--4.7)        2       47     11.8 (8.6--15.0)   10    20    5.3 (3.0--7.6)     7    27     6.8 (4.3--9.2)      1    67   16.7 (13.0--20.3)         0           --
  *Panax ginseng*                 42        16       4.0 (2.1--5.9)        7       26      6.5 (4.1--9.0)     4    28   7.4 (4.8--10.1)     3    41    10.3 (7.3--13.2)    16    15     3.7 (1.9-5.6)     2    41    10.8 (7.7--13.9)
  *Aloe vera*                     172        1       0.3 (0.0--0.7)       25       12      3.0 (1.3--4.7)     1    44   11.6 (8.4--14.9)    2    47    11.8 (8.6--14.9)    37    8     2.0 (0.6--3.4)     4    33     8.7 (5.9--11.5)
  *Foeniculum vulgare ssp.*       31        21       5.2 (3.1--7.4)       11       20      5.0 (2.9--7.2)     2    29   7.7 (5.0--10.4)     8    27     6.8 (4.3--9.2)      4    34    8.5 (5.7--11.2)    33    1     0.3 (0.0--0.8)
  *Valeriana officinalis*         192        1       0.3 (0.0--0.7)       19       16      4.0 (2.1--6.0)     3    29   7.7 (5.0--10.4)    43    11     2.8 (1.2--4.4)      2    51   12.7 (9.4--15.9)    6    17     4.5 (2.4--6.6)
  *Glycine max*                    1        73      18.2 (14.4--22.0)      6       27      6.8 (4.3--9.3)    161   1     0.3 (0.0--0.8)           0           \-           114   2     0.5 (0.0--1.2)           0           \-
  *Melissa officinalis*           14        39       9.7 (6.8--12.6)      12       20      5.0 (2.9--7.2)     7    25    6.6 (4.1--9.1)    74     5     1.3 (0.2--2.3)     18    14    3.5 (1.7--5.3)           0           \-
  *Echinacea purpurea*             3        55      13.7 (10.3--17.1)               0            \-          59    5     1.3 (0.2--2.5)    13    24     6.0 (3.7--8.3)     70    4     1.0 (0.0--2.0)     7    14     3.7 (1.8--5.6)
  *Vaccinium myrtillus*           23        30       7.5 (4.9--10.1)      30       12      3.0 (1.3--4.7)     5    28   7.4 (4.8--10.1)    15    20     5.0 (2.9--7.1)     43    8     2.0 (0.6--3.4)     26    2     0.5 (0.0--1.3)
  *Pimpinella anisum*             16        36       9.0 (6.2--11.8)      28       12      3.0 (1.3--4.7)    38    8     2.1 (0.7--3.6)    21    15     3.8 (1.9--5.6)     11    18    4.5 (2.5--6.5)           0           --
  *Zingiber officinale*           13        41      10.2 (7.3--13.2)      36       11      2.8 (1.2--4.4)    67    5     1.3 (0.2--2.5)     4    30     7.5 (4.9--10.1)    131   2     0.5 (0.0--1.2)           0           --
  *Camellia sinensis*             28        23       5.7 (3.5--8.0)       16       16      4.0 (2.1--6.0)    22    12    3.2 (1.4--4.9)    47    10     2.5 (1.0--4.0)      6    26    6.5 (4.1--8.9)           0           --
  *Vitis vinifera*                34        20       5.0 (2.9--7.1)        5       28      7.0 (4.5--9.6)    28    11    2.9 (1.2--4.6)    127    2     0.5 (0.0--1.2)     12    18    4.5 (2.5--6.5)     13    8     2.1 (0.7--3.6)
  *Taraxacum officinale*          65        10       2.5 (1.0--4.0)       52       10      2.5 (1.0--4.1)     9    21    5.6 (3.2--7.9)    24    15     3.8 (1.9--5.6)      8    24    6.0 (3.7--8.3)           0           --
  *Echinacea angustifolia*         2        55      13.7 (10.3--17.1)               0            --          48    6     1.6 (0.3--2.9)    117    2     0.5 (0.0--1.2)     31    10    2.5 (1.0--4.0)     15    6     1.6 (0.3--2.8)
  *Passiflora incarnata*          75         8       2.0 (0.6--3.4)       62        7      1.8 (0.5--3.1)     6    26    6.9 (4.3--9.4)    65     7     1.8 (0.5--3.0)      5    30    7.5 (4.9--10.0)          0           --
  *Linum usitatissimum*           24        28       7.0 (4.5--9.5)       27       12      3.0 (1.3--)4.7    95    3     0.8 (0.0--1.7)    14    24     6.0 (3.7--8.3)     73    4     1.0 (0.0--2.0)     16    6     1.6 (0.3--2.8)
  *Equisetum arvense*             26        26       6.5 (4.1--8.9)       153       1      0.3 (0.0--0.7)    60    5     1.3 (0.2--2.5)    82     4     1.0 (0.0--2.0)      3    40   10.0 (7.0--12.9)          0           --
  *Allium sativum*                27        25       6.2 (3.9--8.6)       92        3      0.8 (0.0--1.6)    69    4     1.1 (0.0--2.1)    64     7     1.8 (0.5--3.0)      7    24    6.0 (3.7--8.3)     10   12     3.2 (1.4--4.9)
  *Harpagophytum procumbens*                 0             --              9       21      5.3 (3.1--7.5)    20    13    3.4 (1.6--5.3)    55     9     2.3 (0.8--3.7)     40    8     2.0 (0.6--3.4)     5    24     6.3 (3.9--8.8)
  *Olea europaea*                 30        22       5.5 (3.3--7.7)        3       40     10.1 (7.1--13.0)         0           --          84     4     1.0 (0.0--2.0)     42    8     2.0 (0.6--3.4)     36    1     0.3 (0.0--0.8)
  *Glycyrrhiza glabra*            47        14       3.5 (1.7--5.3)       18       16      4.0 (2.1--6.0)    17    14    3.7 (1.8--5.6)    10    26     6.5 (4.1--8.9)     71    4     1.0 (0.0--2.0)           0           --
  *Mentha piperita*                4        47      11.7 (8.6--14.9)      24       14      3.5 (1.7--5.3)    78    4     1.1 (0.0--2.1)    75     5     1.3 (0.2--2.3)     119   2     0.5 (0.0--1.2)           0           --
  *Paullinia cupana*              130        4       1.0 (0.0--2.0)       10       21      5.3 (3.1--7.5)     8    23    6.1 (3.7--8.5)    76     5     1.3 (0.2--2.3)     14    16    4.0 (2.1--5.9)     21    3     0.8 (0.0--1.7)
  *Malpighia glabra*              12        41      10.2 (7.3--13.2)      21       15      3.8 (1.9--5.6)    18    14    3.7 (1.8--5.6)           0           --           169   1     0.3 (0.0--0.7)           0           --
  *Oenothera spec*                10        43      10.7 (7.7--13.8)                0            --                0           --                 0           --           10    20    5.0 (2.9--7.1)     14    7     1.8 (0.5--3.2)
  *Silybum marianum*              190        1       0.3 (0.0--0.7)       35       11      2.8 (1.2--4.4)    15    15    4.0 (2.0--5.9)    23    15     3.8 (1.9--5.6)     19    14    3.5 (1.7--5.3)     9    13     3.4 (1.6--5.3)
  *Matricaria chamomilla*         66        10       2.5 (1.0--4.0)       38       11      2.8 (1.2--4.4)    35    9     2.4 (0.8--3.9)    20    16     4.0 (2.1--5.9)      9    21    5.2 (3.1--7.4)           0           --
  *Citrus limon*                   7        43      10.7 (7.7--13.8)      112       2      0.5 (0.0--1.2)    29    10    2.7 (1.0--4.3)    146    1     0.3 (0.0--0.7)     30    10    2.5 (1.0--4.0)           0           --
  *Urtica dioica*                  9        43      10.7 (7.7--13.8)      53       10      2.5 (1.0--4.1)    133   2     0.5 (0.0--1.3)    89     4     1.0 (0.0--2.0)     66    5     1.2 (0.2--2.3)           0           --
  *Thymus vulgaris*                6        47      11.7 (8.6--14.9)      177       1      0.3 (0.0--0.7)    66    5     1.3 (0.2--2.5)    87     4     1.0 (0.0--2.0)     53    6     1.5 (0.3--2.7)           0           --
  *Salvia officinalis*             8        43      10.7 (7.7--13.8)      80        5      1.3 (0.2--2.4)    82    4     1.1 (0.0--2.1)    66     7     1.8 (0.5--3.0)     124   2     0.5 (0.0--1.2)           0           --
  *Cassia senna*                             0             --                       0            --          11    19    5.0 (2.8--7.2)    11    25     6.3 (3.9--8.6)     22    12    3.0 (1.3--4.7)     17    4     1.1 (0.0--2.1)
  *Rosmarinus officinalis*        64        10       2.5 (1.0--4.0)       34       11      2.8 (1.2--4.4)    129   2     0.5 (0.0--1.3)    12    25     6.3 (3.9--8.6)     25    12    3.0 (1.3--4.7)           0           --
  *Carum carvi*                              0             --              8       23      5.8 (3.5--8.1)    33    9     2.4 (0.8--3.9)     9    26     6.5 (4.1--8.9)     149   1     0.3 (0.0--0.7)           0           --
  *Hypericum perforatum*                     0             --             157       1      0.3 (0.0--0.7)    34    9     2.4 (0.8--3.9)    56     9     2.3 (0.8--3.7)     63    5     1.2 (0.2--2.3)     3    35     9.2 (6.3--12.1)
  *Lavandula angustifolia*        17        34       8.5 (5.8--11.2)      161       1      0.3 (0.0--0.7)          0           --          60     8     2.0 (0.6--3.4)     32    10    2.5 (1.0--4.0)     19    4     1.1 (0.0--2.1)
  *Ribes nigrum*                  20        32       8.0 (5.3--10.6)      172       1      0.3 (0.0--0.7)    44    7     1.9 (0.5--3.2)    176    1     0.3 (0.0--0.7)     24    12    3.0 (1.3--4.7)           0           --

Ranks show the shifts of the botanicals in the position of the overall 1--40 unweighted ranking when stratified by country.

Discussion {#s4}
==========

The present paper reports the findings from a European multi-country survey of PFS consumers: the PlantLIBRA PFS consumer survey. Data on the usage of PFS at the European level are limited, confined in the main to commercial market data [@pone.0092265-European2] as opposed to consumer survey data, as evidenced in the recent review by Bishop and Lewith (2010)[@pone.0092265-Bishop1], where only 13% of population based consumption studies were in Europe. The European Food Safety Authority (EFSA) has recognised the lack of data in the sector and has published a number of reports addressing related issues [@pone.0092265-EuropeanFoodSafety1]--[@pone.0092265-EuropeanFoodSafety2].

To our knowledge this is the first survey of consumers of PFS undertaken in Europe. In total 2359 consumers of PFS were recruited in this cross-sectional retrospective survey. Across all countries prevalence of usage is estimated at 18.8%. Vargas-Murga and colleagues (2011)[@pone.0092265-VargasMurga1] highlighted that comparable data at European level is difficult to identify when reviewing prevalence data from a selected number of European studies, evaluating PFS or CAM usage, with values ranging from 0.8% to 70%. All studies were based on nationally representative samples but the definition of use of supplements varied widely, in some cases being self-defined by the participant and not distinguishing between PFS and HMP. The use of dietary supplements in a European population was measured in the European Prospective Investigation into Cancer and Nutrition (EPIC) study [@pone.0092265-Skeie1]. Usage was measured by completion of a standardised 24-hour dietary recall and included all dietary supplements that met the EU Directive 2002/46/EC. Results indicated significant differences in overall dietary supplement use between countries with herbs/plant-based supplements representing 8--17% of the products used across the ten countries.

The prevalence rate reported here can be compared to rates from surveys conducted in the United States, where data on usage of dietary supplements, including herbal supplements, is collected more routinely. It is similar to the rate reported in the 2002 and 2007 National Health Interview Surveys (NHIS), 18.9% and 17.9% respectively [@pone.0092265-Wu1]; higher than the rates of both the Eisenberg\'s survey [@pone.0092265-Eisenberg1] and the Slone survey [@pone.0092265-Kaufman1], with 14% and 12.1% respectively; and lower than the 2002 Health and Diet Survey (42%) [@pone.0092265-Timbo1] or the 1999 Kaiser Permanent Medical Care Program of Northern California (KPMCP), with a prevalence of 28.3% [@pone.0092265-Schaffer1]. These differences in prevalence across studies may in part be due to the distinct selected population samples, survey methodologies (i.e. sampling methods, data collection techniques) or definitions of usage, as well as possible variations in health beliefs and health behaviour of the different populations of study [@pone.0092265-VargasMurga1], [@pone.0092265-Schaffer1].

Survey respondents were recruited to set quotas for both age and gender to reflect characteristics previously reported for dietary supplement users. Age and gender are significant determinants of the consumption of dietary supplements in general and in botanical products in particular. Previous studies on the use of dietary supplements or other herbal-related use show a higher consumption among women as compared to men [@pone.0092265-MennitiIppolito1], [@pone.0092265-National2], [@pone.0092265-Schaffer1]--[@pone.0092265-Thomas1] and a higher consumption among older adults as compared to younger adults [@pone.0092265-Schaffer1], [@pone.0092265-Foote1]--[@pone.0092265-Bailey1].

Other characteristics of dietary supplements users that have been reported previously in the literature include having higher educational attainment and socioeconomic status [@pone.0092265-Schaffer1], [@pone.0092265-Rock1]--[@pone.0092265-Block1], being less likely to smoke [@pone.0092265-Harrison1], [@pone.0092265-Bailey1], [@pone.0092265-Touvier1], being more physically active [@pone.0092265-Harrison1], [@pone.0092265-Foote1], [@pone.0092265-Bailey1]. Bailey et al. also reported a moderate alcohol consumption (1 drink per day) among dietary supplement users as compared to nonusers. In contrast, a study by Rovira et al. in a southern European population found no differences in lifestyle factors such as physical activity, smoking, and alcohol consumption between dietary supplement users and non-users [@pone.0092265-Rovira1]. Our survey population consists exclusively of PFS consumers, but their responses to a series of questions on health-related lifestyle factors reflect some of the characteristics mentioned above. The majority of PFS consumers perceived their health status to be "very good or good", reflecting results reported in a number of studies on dietary supplement users [@pone.0092265-Bailey1] and CAM and dietary supplement users [@pone.0092265-Schaffer1], where the answer "very good or excellent" has been reported for self-reported health status.

The survey results indicate that most consumers reported using one PFS product in the preceding 12 months, with 12% using two products and 4% using more than two. Individual country data show that Finnish consumers use more than one product and PFS with more than one botanical component, and the opposite is observed in the United Kingdom, where about 90% of the consumers use only one PFS and the products contain mostly only one botanical. In the United States, recent studies have reported that about half of the adults report using one or more dietary supplements [@pone.0092265-Bailey1], [@pone.0092265-Picciano1]. One of these studies also found that over half of dietary supplement consumers used a single-botanical product and one third used one multi-botanical product [@pone.0092265-Bailey1]. Similar results were found in our survey across all countries i.e. smaller numbers of consumers reported using two or more single-botanical products (4.4%) and two or more single- and multi-botanical products (11.9%).

A wide variety of botanicals (491) is used in PFS consumed by the respondents in this survey. Overall raw data show that the most frequently (n\>100) used botanicals in descending order are *Ginkgo biloba* (ginkgo), *Oenothera biennis* (evening primrose), *Cynara scolymus* (artichoke), *Panax ginseng* (ginseng), *Aloe vera, Foeniculum vulgare* (fennel), *Valeriana officinalis* (valeriana), *Glycine max* (soybean), *Melissa officinalis* (lemon balm), *Echinacea purpurea* (echinacea) *and Vaccinium myrtillus* (blueberry). These results reflect some commercial data which reported that ginkgo followed by echinacea, garlic and ginseng were the four most commercially important botanicals in the combined markets of seventeen EC Member States. In this data, echinacea and ginkgo were part of the composition of products registered as medicines [@pone.0092265-European2], [@pone.0092265-VargasMurga1], which were excluded from our survey. Similarly, the US Food and Drug Administration 2002 Health and Diet Survey, also a 12-month retrospective study, reported the same four herbs/botanicals/or other nonvitamin-nonmineral dietary supplements being the most used by its adult population -- although in the following order: echinacea, garlic, ginkgo and ginseng (the latter including tea) [@pone.0092265-Timbo1]. Schaffer et al. also reported echinacea as the most consumed botanical in the Californian 1999 KPMCP survey, followed by ginkgo [@pone.0092265-Schaffer1]. Differences between countries are more evident; the top list of botanicals contained in PFS for each single country complies little with the ranking of the overall data. As mentioned earlier, data were not weighted by country population size because of the study methodology which included very similar country-sample sizes of PFS consumers only, therefore caution is needed when drawing conclusions from these results at the overall 6-country level. Overall data merely describes the collected pooled data from all 6 countries. However, if the overall ranking data were to be weighted by the population size -for example the 1--5 ranking data-, the positions of the botanicals would have been only slightly altered, with *Oenothera biennis* (evening primrose) being the most consumed one, followed by *Cynara scolymus* (artichoke) *Ginkgo biloba* (ginkgo), *Panax ginseng* (ginseng) and *Aloe vera* (aloe).

The results of the survey highlight clear differences between countries in terms of the botanicals used by consumers as PFS. This may reflect the fact that the current legal and regulatory framework for botanicals has a major influence on the nature of the local PFS markets. The EU Directive 2002/46/EC does not provide a clear definition of what is encompassed by the term 'other substance with a nutritional or physiological effect\', although it is generally accepted that botanicals and their extracts fall into this category. Current legislation varies across Europe, with significant differences in the botanical species permitted in PFS. These issues were highlighted in a recent review of the regulations applicable to PFS in the European Union by Silano et al. [@pone.0092265-Silano1]. They provide examples of the different national approaches for the use of selected botanicals in food supplements in the EU Member States.

To illustrate the above complexity, in Germany, food supplements are regulated by the German Regulation on Food Supplements [@pone.0092265-Verordnung1] and the German Law on Food and Feed [@pone.0092265-Lebensmittel1]. Positive lists are available for minerals and vitamins. Food supplements have to be registered with the Federal Office of Consumer Protection and Food Safety [@pone.0092265-Federal1]. The BVL maintains a list of plants which are either classified as a food or a medicinal product, and which is neither considered complete nor legally binding [@pone.0092265-Federal1]. Data on the intake of PFS in Germany is limited and, despite food supplement intake being recorded in recent health and nutrition surveys [@pone.0092265-Finger1]--[@pone.0092265-Max1], no specific data was published on PFS intake. The results from the PlantLIBRA consumer survey do not include *Valeriana officinalis* in the German top list of botanicals used in PFS, whereas 1852 medicinal products containing Valerian exist on the market [@pone.0092265-Lebensmittel1]. The absence of *Valeriana officinalis* in the German list of botanicals can be explained by its dominant presence as a HMP in the German market.

The results of this survey represent some of the first data on the usage of PFS at European level, thus addressing the existing deficit of such data by collecting retrospective data directly from consumers in six European countries. The benefits of the data collection instrument used in this study included that it was relatively straightforward to administer, did not alter habitual usage patterns and allowed the classification of individuals into categories of usage. However, the results must be considered in the light of their limitations. The sample population comprises exclusively of PFS consumers, recruited to meet very specific inclusion criteria and hence no comparisons can be made with the general population. Future studies should seek to compare users and non-users of PFS.

Further limitations relate to the retrospective nature of the data being collected. In many cases respondents needed to rely on memory to report usage of products in the preceding 12 months. Where products are available for inspection at data collection, there is a need for careful recording of product details to ensure accurate coding. The lack of a comprehensive product database containing reliable ingredient information meant a bespoke database needed to be created. Future studies should seek to collect prospective data. Prospective dietary intake surveys offer an ideal opportunity to collect data on supplement use in conjunction with data on food and beverages. Care needs to be taken to collect sufficiently detailed information about ingredients and amounts consumed. For example, in the US, the Alternative Health/CAM supplement of the National Health Interview Survey (NHIS) is part of an annual, nationally representative survey of US adults. It contains data on adults\' use of 10 herbs most commonly taken to treat a specific health condition in the preceding 12 months [@pone.0092265-Bardia1]; the survey has a separate section on dietary supplements and distinguishes "natural herbs" from vitamins and minerals. The authors would like to encourage researchers to implement future surveys/studies which are necessary to overcome the bottlenecks in PFS risk and benefit assessments at the European level.
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